CD19 and acute lymphoblastic leukemia: It is difficult to make a direct comparison of clinical efficacy between allogeneic HSCT and CD19-CAR-T cell therapy, as HSCT improves outcomes in specific ALL populations, while CD19-CAR-T cell therapy has demonstrated efficacy in patients who failed allogeneic HSCT and/or are not eligible for HSCT [176].